Phase I Interim Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory (R/R) Multiple Myeloma (MM)

Autor: Kumar, S., Vij, R., Kaufman, J.L., Mikhael, J., Facon, T., Moreau, P., Amiot, M., Alzate, S., Morris, L., Ross, J., Dunbar, M., Zhu, M., Agarwal, S., Leverson, J., Enschede, S., Humerickhouse, R., Touzeau, C.
Zdroj: In Clinical Lymphoma Myeloma and Leukemia September 2015 15 Supplement 3:e81-e82
Databáze: ScienceDirect
Externí odkaz: